共 231 条
[1]
Redfield RR(2016)Current outcomes of chronic active antibody mediated rejection - a large single center retrospective review using the updated BANFF 2013 criteria Hum Immunol 77 346-352
[2]
Ellis TM(2020)Recommended treatment for antibody-mediated rejection after kidney transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group Transplantation. 104 911-922
[3]
Zhong W(2020)The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection Am J Transplant 20 2318-2331
[4]
Scalea JR(2021)Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation Transplantation. 105 648-659
[5]
Zens TJ(2002)Death after graft loss: an important late study endpoint in kidney transplantation Am J Transplant 2 970-974
[6]
Mandelbrot D(2005)Patient survival following renal transplant failure in Canada Am J Transplant 5 1719-1724
[7]
Schinstock CA(2018)Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer Nat Rev Immunol 18 773-789
[8]
Mannon RB(2020)Interleukin-6 signalling in health and disease F1000Res. 9 F1000-44
[9]
Budde K(2020)Clazakizumab (anti-IL-6) induces FOXP3+ tregs in highly HLA sensitized patients receiving HLAI kidney transplantation (NCT03380962) Transplantation 104 S105-3080
[10]
Chong AS(2017)Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade Transplantation. 101 32-143